Skip to main content

Advertisement

Articles

Page 2 of 34

  1. Content type: Original investigation

    Myocardial energetic efficiency (MEE), is a strong predictor of CV events in hypertensive patient and is reduced in patients with diabetes and metabolic syndrome. We hypothesized that severity of insulin resis...

    Authors: Costantino Mancusi, Giovanni de Simone, Lyle G. Best, Wenyu Wang, Ying Zhang, Mary J. Roman, Elisa T. Lee, Barbara V. Howard and Richard B. Devereux

    Citation: Cardiovascular Diabetology 2019 18:56

    Published on:

  2. Content type: Original investigation

    Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2...

    Authors: Maurice B. Bizino, Ingrid M. Jazet, Jos J. M. Westenberg, Huub J. van Eyk, Elisabeth H. M. Paiman, Jan W. A. Smit and Hildebrandus J. Lamb

    Citation: Cardiovascular Diabetology 2019 18:55

    Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2019 18:101

  3. Content type: Review

    With an increasing global burden of coronary artery disease (CAD), early detection and timely management of risk factors are crucial to reduce morbidity and mortality in such patients. Diabetes mellitus (DM) i...

    Authors: Fei Luo, Avash Das, Jingfei Chen, Panyun Wu, Xiangping Li and Zhenfei Fang

    Citation: Cardiovascular Diabetology 2019 18:54

    Published on:

  4. Content type: Original investigation

    Prediabetes is a well-established risk factor for progression to overt diabetes mellitus (DM), which is in turn associated with development of hypertension (HTN) and vice versa. However, the role of prediabete...

    Authors: Mika Geva, Gadi Shlomai, Anat Berkovich, Elad Maor, Avshalom Leibowitz, Alexander Tenenbaum and Ehud Grossman

    Citation: Cardiovascular Diabetology 2019 18:53

    Published on:

  5. Content type: Original investigation

    Despite revascularisation, a large proportion of acute coronary syndrome (ACS) patients continue to experience major adverse cardiovascular events (MACEs), which are worsened by diabetes mellitus (DM). Fibrino...

    Authors: Lisha Zhang, Chenbo Xu, Junhui Liu, Xiaofang Bai, Ruifeng Li, Lijun Wang, Juan Zhou, Yue Wu and Zuyi Yuan

    Citation: Cardiovascular Diabetology 2019 18:52

    Published on:

  6. Content type: Original investigation

    Evidence from imaging studies suggests a high prevalence of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM). However, there are no criteria for initiating screening for CAD in th...

    Authors: Shreenidhi M. Venuraju, Avijit Lahiri, Anand Jeevarethinam, Mark Cohen, Daniel Darko, Devaki Nair, Miranda Rosenthal and Roby D. Rakhit

    Citation: Cardiovascular Diabetology 2019 18:51

    Published on:

  7. Content type: Original investigation

    To investigate the effect of visit-to-visit fasting plasma glucose (FPG) variability on the left cardiac structure and function in patients with type 2 diabetes mellitus (T2DM).

    Authors: Xixiang Tang, Junlin Zhong, Hui Zhang, Yanting Luo, Xing Liu, Long Peng, Yanling Zhang, Xiaoxian Qian, Boxiong Jiang, Jinlai Liu, Suhua Li and Yanming Chen

    Citation: Cardiovascular Diabetology 2019 18:50

    Published on:

  8. Content type: Original investigation

    Type 2 diabetes mellitus (T2DM) is associated with a hypercoagulable state and increased neutrophil extracellular traps formation (NETosis). We investigated predictors of NETosis and cell death markers in circ...

    Authors: Agata H. Bryk, Shannon M. Prior, Krzysztof Plens, Malgorzata Konieczynska, Jerzy Hohendorff, Maciej T. Malecki, Saulius Butenas and Anetta Undas

    Citation: Cardiovascular Diabetology 2019 18:49

    Published on:

  9. Content type: Review

    The importance of triglycerides (TG) level as a risk factor for cardiovascular diseases (CVD) has been extensively investigated in the general population; however, their relationship in patients with type 2 di...

    Authors: Xiaofeng Ye, Wen Kong, Mohammad Ishraq Zafar and Lu-Lu Chen

    Citation: Cardiovascular Diabetology 2019 18:48

    Published on:

  10. Content type: Review

    The cardiovascular (CV) safety in terms of heart failure among different classes of treatment remains largely unknown. We sought to assess the comparative effect of these agents on heart failure outcomes.

    Authors: Da-ya Yang, Xin He, Hui-wei Liang, Shao-zhao Zhang, Xiang-bin Zhong, Chu-fan Luo, Zhi-min Du, Jian-gui He, Xiao-dong Zhuang and Xin-xue Liao

    Citation: Cardiovascular Diabetology 2019 18:47

    Published on:

  11. Content type: Original investigation

    SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2 diabetes and have been shown to reduce body weight. However, it is unclear which body compartments are reduced and to what extent.

    Authors: Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche and Ferruh Artunc

    Citation: Cardiovascular Diabetology 2019 18:46

    Published on:

  12. Content type: Original investigation

    Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and ...

    Authors: Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen and An-Sheng Lee

    Citation: Cardiovascular Diabetology 2019 18:45

    Published on:

  13. Content type: Original investigation

    Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.

    Authors: Agnes Bosch, Christian Ott, Susanne Jung, Kristina Striepe, Marina V. Karg, Dennis Kannenkeril, Thomas Dienemann and Roland E. Schmieder

    Citation: Cardiovascular Diabetology 2019 18:44

    Published on:

  14. Content type: Original investigation

    Patients with type 1 diabetes (T1DM) typically have normal or even elevated plasma high density lipoprotein (HDL) cholesterol concentrations; however, HDL protein composition can be altered without a change in...

    Authors: Evgenia Gourgari, Junfeng Ma, Martin P. Playford, Nehal N. Mehta, Radoslav Goldman, Alan T. Remaley and Scott M. Gordon

    Citation: Cardiovascular Diabetology 2019 18:43

    Published on:

  15. Content type: Original investigation

    We aimed to compare early and late outcomes after carotid endarterectomy (CEA) between Korean type 2 diabetic and non-diabetic patients and to investigate the impact of diabetes on the overall incidence of car...

    Authors: Min-Jae Jeong, Hyunwook Kwon, Chang Hee Jung, Sun U. Kwon, Min-Ju Kim, Youngjin Han, Tae-Won Kwon and Yong-Pil Cho

    Citation: Cardiovascular Diabetology 2019 18:41

    Published on:

  16. Content type: Original investigation

    Diabetic nephropathy (DN) is characterized by glomerular and tubulointerstitial injury, proteinuria and remodeling. Here we examined whether the combination of an inhibitor of neprilysin (sacubitril), a natriu...

    Authors: Javad Habibi, Annayya R. Aroor, Nitin A. Das, Camila M. Manrique-Acevedo, Megan S. Johnson, Melvin R. Hayden, Ravi Nistala, Charles Wiedmeyer, Bysani Chandrasekar and Vincent G. DeMarco

    Citation: Cardiovascular Diabetology 2019 18:40

    Published on:

  17. Content type: Original investigation

    The efficacy of cell transplantation in heart failure is reportedly modest, but adjuvant drugs combined with cell therapy may improve this efficacy. Peroxisome proliferator-activated receptor (PPAR)γ, one of t...

    Authors: Daisuke Mori, Shigeru Miyagawa, Ryohei Matsuura, Nagako Sougawa, Satsuki Fukushima, Takayoshi Ueno, Koichi Toda, Toru Kuratani, Koichi Tomita, Norikazu Maeda, Iichiro Shimomura and Yoshiki Sawa

    Citation: Cardiovascular Diabetology 2019 18:39

    Published on:

  18. Content type: Original investigation

    Using a meta-analysis of randomized controlled trials (RCTs), this study aimed to investigate the efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator, i...

    Authors: Satoshi Ida, Ryutaro Kaneko and Kazuya Murata

    Citation: Cardiovascular Diabetology 2019 18:38

    Published on:

  19. Content type: Original investigation

    Subtle impairments in left ventricular (LV) function and geometry are common findings in individuals with diabetes. However, whether these impairments precede the development of diabetes mellitus (DM) is not e...

    Authors: Daniel Modin, Rasmus Møgelvang, Peter Godsk Jørgensen, Magnus Thorsten Jensen, Jelena P. Seferovic and Tor Biering-Sørensen

    Citation: Cardiovascular Diabetology 2019 18:37

    Published on:

  20. Content type: Original investigation

    Because weight control is a cornerstone of diabetes management, it is important to understand the relationship of weight change to risk of cardiovascular disease (CVD) among patients with type 2 diabetes melli...

    Authors: Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam and Hyuk-Sang Kwon

    Citation: Cardiovascular Diabetology 2019 18:36

    Published on:

  21. Content type: Original investigation

    This pathophysiological study addressed the hypothesis that soluble epoxide hydrolase (sEH), which metabolizes the vasodilator and anti-inflammatory epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic ...

    Authors: Thomas Duflot, Lucile Moreau-Grangé, Clothilde Roche, Michèle Iacob, Julien Wils, Isabelle Rémy-Jouet, Anne-Françoise Cailleux, Matthieu Leuillier, Sylvanie Renet, Dongyang Li, Christophe Morisseau, Fabien Lamoureux, Vincent Richard, Gaëtan Prévost, Robinson Joannidès and Jérémy Bellien

    Citation: Cardiovascular Diabetology 2019 18:35

    Published on:

  22. Content type: Original investigation

    Exercise, when performed on a regular basis, is a well-accepted strategy to improve vascular function in patients with type 2 diabetes. However, the exercise intensity that yields maximal adaptations on struct...

    Authors: João P. Magalhães, Xavier Melo, Inês R. Correia, Rogério T. Ribeiro, João Raposo, Hélder Dores, Manuel Bicho and Luís B. Sardinha

    Citation: Cardiovascular Diabetology 2019 18:34

    Published on:

  23. Content type: Original investigation

    To evaluate the characteristics of type 2 diabetes (T2DM) patients with or without chronic kidney disease (CKD) in Germany.

    Authors: Peter Bramlage, Stefanie Lanzinger, Gesine van Mark, Eva Hess, Simon Fahrner, Christoph H. J. Heyer, Mathias Friebe, Jochen Seufert, Thomas Danne and Reinhard W. Holl

    Citation: Cardiovascular Diabetology 2019 18:33

    Published on:

  24. Content type: Retraction Note

    The authors have retracted this article [1] because they have identified serious errors in their data analysis which change the conclusions of their study. All authors agree with this retraction.

    Authors: Kyoung Min Kim, Kyong Yeun Jung, Han Mi Yun, Seo Young Lee, Tae Jung Oh, Hak Chul Jang and Soo Lim

    Citation: Cardiovascular Diabetology 2019 18:32

    Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:146

  25. Content type: Original investigation

    Diabetes mellitus (DM) adversely affects morbidity and mortality for major atherosclerosis-related cardiovascular diseases and is associated with increased risk for the development of aortic stenosis. Clinical...

    Authors: Eilon Ram, Alexander Kogan, Shany Levin, Enrique Z. Fisman, Alexander Tenenbaum, Ehud Raanani and Leonid Sternik

    Citation: Cardiovascular Diabetology 2019 18:31

    Published on:

  26. Content type: Commentary

    The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25–26 October 2018. As in previous years, this summit served as a refe...

    Authors: Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa Lalic, Dario Rahelic, Jan Skrha, Paul Valensi and Antonio Ceriello

    Citation: Cardiovascular Diabetology 2019 18:30

    Published on:

  27. Content type: Original investigation

    Cardiovascular autonomic neuropathy (CAN) is a major cause of morbidity and mortality in diabetes patients. Although several risk factors for CAN progression have been established, whether CAN is reversible re...

    Authors: Ji Eun Jun, Seung-Eun Lee, Min Sun Choi, Sung Woon Park, You-Cheol Hwang and Jae Hyeon Kim

    Citation: Cardiovascular Diabetology 2019 18:29

    Published on:

  28. Content type: Original investigation

    To determine the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) on the risk of major cardiocerebrovascular and renal outcomes compared with sulfonylurea (SU) combined with metformin in patients with type 2...

    Authors: Kyoung Jin Kim, Jimi Choi, Juneyoung Lee, Jae Hyun Bae, Jee Hyun An, Hee Young Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim and Nam Hoon Kim

    Citation: Cardiovascular Diabetology 2019 18:28

    Published on:

  29. Content type: Original investigation

    Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was th...

    Authors: Guillaume Besch, Sebastien Pili-Floury, Caroline Morel, Martine Gilard, Guillaume Flicoteaux, Lucie Salomon du Mont, Andrea Perrotti, Nicolas Meneveau, Sidney Chocron, Francois Schiele, Herve Le Breton, Emmanuel Samain and Romain Chopard

    Citation: Cardiovascular Diabetology 2019 18:27

    Published on:

  30. Content type: Original investigation

    The prevalence of asymptomatic coronary artery disease (CAD) in type 2 diabetes (T2D) is unclear. We investigated the extent and prevalence of asymptomatic CAD in T2D patients by utilizing invasive coronary an...

    Authors: Satish Arora, Anne Pernille Ofstad, Geir R. Ulimoen, Kåre I. Birkeland, Knut Endresen, Lars Gullestad and Odd Erik Johansen

    Citation: Cardiovascular Diabetology 2019 18:26

    Published on:

  31. Content type: Original investigation

    Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) remains challenging even with modern drug-eluting stents (DES) due to high rates of repeat revascularization. Everolimus-eluting...

    Authors: T. M. Hommels, R. S. Hermanides, S. Rasoul, B. Berta, A. J. J. IJsselmuiden, G. A. J. Jessurun, E. Benit, B. Pereira, G. De Luca and E. Kedhi

    Citation: Cardiovascular Diabetology 2019 18:25

    Published on:

  32. Content type: Original investigation

    In patients with Normal Glucose Tolerance (NGT) some causes of ischemic heart disease (IHD) were not completely investigated. The role both of metabolic milieu and adipokines in IHD progression was not fully inve...

    Authors: Ferdinando Carlo Sasso, Pia Clara Pafundi, Raffaele Marfella, Paolo Calabrò, Federico Piscione, Fulvio Furbatto, Giovanni Esposito, Raffaele Galiero, Felice Gragnano, Luca Rinaldi, Teresa Salvatore, Michele D’Amico, Luigi Elio Adinolfi and Celestino Sardu

    Citation: Cardiovascular Diabetology 2019 18:24

    Published on:

  33. Content type: Correction

    Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 bas...

    Authors: Andrei C. Sposito, Otávio Berwanger, Luiz Sérgio F. de Carvalho and José Francisco Kerr Saraiva

    Citation: Cardiovascular Diabetology 2019 18:23

    Published on:

    The original article was published in Cardiovascular Diabetology 2018 17:157

  34. Content type: Original investigation

    Patients with type 2 diabetes mellitus are at an increased risk of adverse cardiovascular events compared to those without diabetes. The timing, relative to disease onset, and degree of glycemic control that r...

    Authors: Jaskanwal D. Sara, Riad Taher, Nikhil Kolluri, Adrian Vella, Lilach O. Lerman and Amir Lerman

    Citation: Cardiovascular Diabetology 2019 18:22

    Published on:

  35. Content type: Original investigation

    There is a mutual interaction between inflammation and endocrine disorders in the development of coronary artery disease (CAD). Growth differentiation factor-15 (GDF-15) is associated with CAD, and the effects...

    Authors: Huan Liu, Yongnan Lyu, Di Li, Yan Cui, Yun Huang, Wen Dai and Yan Li

    Citation: Cardiovascular Diabetology 2019 18:21

    Published on:

  36. Content type: Review

    Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 ...

    Authors: Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi and Andrea Giaccari

    Citation: Cardiovascular Diabetology 2019 18:20

    Published on:

  37. Content type: Original investigation

    Impaired glucose tolerance (IGT) is a risk factor for the development of diabetes and related complications that ensue. Early identification of at-risk individuals might be beneficial to reduce or delay the pr...

    Authors: Lucia La Sala, Simona Mrakic-Sposta, Elena Tagliabue, Francesco Prattichizzo, Stefano Micheloni, Elena Sangalli, Claudia Specchia, Anna Chiara Uccellatore, Silvia Lupini, Gaia Spinetti, Paola de Candia and Antonio Ceriello

    Citation: Cardiovascular Diabetology 2019 18:18

    Published on:

  38. Content type: Original investigation

    Soluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic va...

    Authors: Andrea Maria Maresca, Luigina Guasti, Sara Bozzini, Christian Mongiardi, Nicolò Tandurella, Rossana Corso, Francesco G. Zerba, Alessandro Squizzato, Leonardo Campiotti, Francesco Dentali, Catherine Klersy, Anna M. Grandi and Colomba Falcone

    Citation: Cardiovascular Diabetology 2019 18:17

    Published on:

  39. Content type: Original investigation

    Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown ...

    Authors: Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan and Ann-Cathrine Jönsson-Rylander

    Citation: Cardiovascular Diabetology 2019 18:16

    Published on:

  40. Content type: Original investigation

    Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reporte...

    Authors: Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun and Liming Chen

    Citation: Cardiovascular Diabetology 2019 18:15

    Published on:

  41. Content type: Original investigation

    Carotid artery intima-media thickness (cIMT) progression is a surrogate marker of atherosclerosis with a high predictive value for future CVD risk. This study evaluates the comparative efficacies of lipid lowe...

    Authors: Rongzhong Huang, Kerry Mills, Julio Romero, Yan Li, Zicheng Hu, Yu Cao, Hua Huang, Yu Xu and Lihong Jiang

    Citation: Cardiovascular Diabetology 2019 18:14

    Published on:

  42. Content type: Original investigation

    The diabetic heart undergoes remodelling contributing to an increased incidence of heart failure in individuals with diabetes at a later stage. The molecular regulators that drive this process in the diabetic ...

    Authors: Shruti Rawal, Prashanth Thevakar Nagesh, Sean Coffey, Isabelle Van Hout, Ivor F. Galvin, Richard W. Bunton, Philip Davis, Michael J. A. Williams and Rajesh Katare

    Citation: Cardiovascular Diabetology 2019 18:13

    Published on:

  43. Content type: Original investigation

    Increasing evidence has suggested that the presence of remnant lipoproteins is a significant risk factor for atherosclerosis. Remnant lipoproteins are lipoproteins that are rich in triglycerides (TGs), and the...

    Authors: Zheng Qin, Kuo Zhou, Yue-ping Li, Jian-long Wang, Wan-jun Cheng, Cheng-ping Hu, Chao Shi, Hua He and Yu-jie Zhou

    Citation: Cardiovascular Diabetology 2019 18:11

    Published on:

  44. Content type: Commentary

    Novel studies have increased our knowledge regarding optimal treatment options in diabetes. Key studies that have broadened our knowledge about optimal treatment options in diabetes in recent years are cardiov...

    Authors: Katharina Fritzen and Oliver Schnell

    Citation: Cardiovascular Diabetology 2019 18:10

    Published on:

  45. Content type: Original investigation

    Reports on body mass index (BMI) trajectories from childhood into late adolescence, their determinants, and subsequent cardiometabolic risk markers, particularly among European populations have been few. Moreo...

    Authors: Kolade Oluwagbemigun, Anette E. Buyken, Ute Alexy, Matthias Schmid, Christian Herder and Ute Nöthlings

    Citation: Cardiovascular Diabetology 2019 18:9

    Published on:

  46. Content type: Original investigation

    Sortilin is a 95-kDa protein which has recently been linked to circulating cholesterol concentration and lifetime risk of developing significant atherosclerotic disease. Sortilin is found inside different cell...

    Authors: Federico Biscetti, Nicola Bonadia, Francesco Santini, Flavia Angelini, Elisabetta Nardella, Dario Pitocco, Angelo Santoliquido, Marco Filipponi, Raffaele Landolfi and Andrea Flex

    Citation: Cardiovascular Diabetology 2019 18:5

    Published on:

Annual Journal Metrics

Advertisement